Cardiff Oncology (CRDF) Payables (2011 - 2026)

Cardiff Oncology has reported Payables for 15 years, with the latest figure at $8.1 million in Q4 2025.

• Quarterly Payables rose 67.75% year-over-year to $8.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.1 million (up 67.75% YoY) and the FY2025 annual result came in at $8.1 million, up 67.75% from the prior year.
• Payables grew to $8.1 million in Q4 2025 per CRDF's latest filing, from $2.4 million in the prior quarter.
• Over five years, Payables peaked at $8.1 million in Q4 2025 and troughed at $396000.0 in Q3 2021.
• A 5-year average of $3.0 million and a median of $2.3 million in 2023 frame the typical range for Payables.
• The sharpest annual moves came in 2021 and 2022: Payables tumbled 56.73% in 2021, then jumped 259.85% in 2022.
• Over 5 years, Payables stood at $1.4 million in 2021, then soared by 35.93% to $2.0 million in 2022, then climbed by 0.51% to $2.0 million in 2023, then soared by 145.22% to $4.8 million in 2024, then soared by 67.75% to $8.1 million in 2025.
• According to Business Quant data, Payables over the past three periods registered $8.1 million, $2.4 million, and $6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.